Vered Fuchs
YOU?
Author Swipe
Characterization of the xeno-GVHD response generated by advanced lung cancer patient peripheral blood mononuclear cells in NSG-SGM3 mice Open
This study demonstrates significant differences in xeno-GVHD progression between advance-stage NSCLC patients and HDs, likely influenced by the patient's treatment histories. These findings improve our understanding of hu-PBL models for NS…
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration Open
Purpose In the pursuit of creating personalized and more effective treatment strategies for lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as preclinical platforms that can recapitulate the specific patient’s …
Characterization of the Xeno-GVHD Response Generated by Lung Cancer Patient PBMCs in NSG-SGM3 Mice Open
Humanized mouse models based on PBMC transplants have become a critical preclinical platform for NSCLC investigation. However, the emergence of xeno-GVHD poses challenges that need clarification. In this study, we explore clinical and mole…
Patient-derived xenograft models of human non-small cell lung cancer: pre-clinical and clinical factors for consideration Open
Despite the widespread utilization of Patient-Derived Xenografts (PDXs) as preclinical platforms in lung cancer research, there are concerns regarding their capability to accurately represent the tumor's clinical and molecular features acr…
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study Open
Background Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial activity of osimertinib is documented in larger trials, a prospect…
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer Open
Lung cancer has historically been the main responsible for cancer associated deaths. Owing to this is our current inability to screen for and diagnose early pathological findings, preventing us from a timely intervention when cure is still…
Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma) Open
The new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 …
Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases Open
Background Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction …